Table of contents
Volume 96, Issue 2
Published online 23 January 2007 (183-401)
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Genetics and Genomics |
Letters to the Editor |
Book Review
Minireviews
Host epigenetic modifications by oncogenic viruses FREE
J M Flanagan
Br J Cancer 96: 183-188; advance online publication, December 19, 2006; doi:10.1038/sj.bjc.6603516
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents FREE
J P B O'Connor, A Jackson, G J M Parker and G C Jayson
Br J Cancer 96: 189-195; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603515
ASPP: a new family of oncogenes and tumour suppressor genes FREE
A Sullivan and X Lu
Br J Cancer 96: 196-200; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603525
The decatenation checkpoint FREE
M Damelin and T H Bestor
Br J Cancer 96: 201-205; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603537
Clinical Studies
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment FREE
N Starling, D Tilden, J White and D Cunningham
Br J Cancer 96: 206-212; doi:10.1038/sj.bjc.6603561
The relationship between patient physiology and cancer-specific survival following curative resection of colorectal cancer FREE
J T Jenkins, G O'Neill and C G Morran
Br J Cancer 96: 213-217; doi:10.1038/sj.bjc.6603560
Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme FREE
S Ciatto, F Martinelli, G Castiglione, P Mantellini, T Rubeca, G Grazzini, A G Bonanomi, M Confortini and M Zappa
Br J Cancer 96: 218-221; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603534
C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases FREE
V K H Wong, H Z Malik, Z Z R Hamady, A Al-Mukhtar, D Gomez, K R Prasad, G J Toogood and J P A Lodge
Br J Cancer 96: 222-225; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603558
Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review FREE
J Bryant, J Picot, L Baxter, G Levitt, I Sullivan and A Clegg
Br J Cancer 96: 226-230; doi:10.1038/sj.bjc.6603562
Translational Therapeutics
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells FREE
O H Temmink, E K Hoebe, K van der Born, S P Ackland, M Fukushima and G J Peters
Br J Cancer 96: 231-240; doi:10.1038/sj.bjc.6603549
Role of the progesterone receptor for paclitaxel resistance in primary breast cancer FREE
M Schmidt, E Bremer, D Hasenclever, A Victor, M Gehrmann, E Steiner, I B Schiffer, S Gebhardt, H-A Lehr, M Mahlke, M Hermes, A Mustea, B Tanner, H Koelbl, H Pilch and J G Hengstler
Br J Cancer 96: 241-247; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603538
Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis FREE
R D Verschoyle, P Greaves, H Cai, R E Edwards, W P Steward and A J Gescher
Br J Cancer 96: 248-254; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603539
Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma FREE
N Horie, H Murata, S Kimura, H Takeshita, T Sakabe, T Matsui, T Maekawa, T Kubo and S Fushiki
Br J Cancer 96: 255-261; doi:10.1038/sj.bjc.6603548
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases FREE
S D Killeen, E J Andrews, J H Wang, T Wu, W Schmalix, B Muehlenweg and H P Redmond
Br J Cancer 96: 262-268; doi:10.1038/sj.bjc.6603550
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms FREE
M-E Legrier, S Oudard, J-G Judde, C Guyader, G de Pinieux, K Boyé, P de Cremoux, B Dutrillaux and M-F Poupon
Br J Cancer 96: 269-276; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603553
Molecular Diagnostics
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer FREE
S Kamoshida, M Suzuki, R Shimomura, Y Sakurai, Y Komori, I Uyama and Y Tsutsumi
Br J Cancer 96: 277-283; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603546
Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity FREE
C M McClelland and W J Gullick
Br J Cancer 96: 284-289; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603544
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer FREE
K Uno, S Homma, T Satoh, K Nakanishi, D Abe, K Matsumoto, A Oki, H Tsunoda, I Yamaguchi, T Nagasawa, H Yoshikawa and K Aonuma
Br J Cancer 96: 290-295; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603552
Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation FREE
T G P Grunewald, U Kammerer, C Winkler, D Schindler, A Sickmann, A Honig and E Butt
Br J Cancer 96: 296-305; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603545
Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group FREE
S Kommoss, A du Bois, R Ridder, M J Trunk, D Schmidt, J Pfisterer and F Kommoss for the AGO-OVAR
Br J Cancer 96: 306-313; doi:10.1038/sj.bjc.6603531
Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients FREE
S Hosono, H Kajiyama, M Terauchi, K Shibata, K Ino, A Nawa and F Kikkawa
Br J Cancer 96: 314-320; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603533
Molecular profiling of cervical cancer progression FREE
T Hagemann, T Bozanovic, S Hooper, A Ljubic, V I F Slettenaar, J L Wilson, N Singh, S A Gayther, J H Shepherd and P O A Van Trappen
Br J Cancer 96: 321-328; doi:10.1038/sj.bjc.6603543
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays FREE
S Garcia, J-P Dalès, J Jacquemier, E Charafe-Jauffret, D Birnbaum, L Andrac-Meyer, M-N Lavaut, C Allasia, S Carpentier-Meunier, P Bonnier and C Charpin-Taranger
Br J Cancer 96: 329-335; doi:10.1038/sj.bjc.6603569
Genetics and Genomics
Mutations in BHD and TP53 genes, but not in HNF1
gene, in a large series of sporadic chromophobe renal cell carcinoma FREE
S Gad, S H Lefèvre, S K Khoo, S Giraud, A Vieillefond, V Vasiliu, S Ferlicot, V Molinié, Y Denoux, N Thiounn, Y Chrétien, A Méjean, M Zerbib, G Benoît, J M Hervé, G Allègre, B Bressac-de Paillerets, B T Teh and S Richard
Br J Cancer 96: 336-340; advance online publication, November 28, 2006; doi:10.1038/sj.bjc.6603492
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy FREE
J-Y Pierga, J S Reis-Filho, S J Cleator, T Dexter, A MacKay, P Simpson, K Fenwick, M Iravani, J Salter, M Hills, C Jones, A Ashworth, I E Smith, T Powles and M Dowsett
Br J Cancer 96: 341-351; advance online publication, November 28, 2006; doi:10.1038/sj.bjc.6603483
Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers FREE
M Georgitsi, A Karhu, R Winqvist, T Visakorpi, K Waltering, P Vahteristo, V Launonen and L A Aaltonen
Br J Cancer 96: 352-356; doi:10.1038/sj.bjc.6603573
A physical analysis of the Y chromosome shows no additional deletions, other than Gr/Gr, associated with testicular germ cell tumour FREE
R Linger, D Dudakia, R Huddart, D Easton, D T Bishop, M R Stratton and E A Rapley
Br J Cancer 96: 357-361; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603557
Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects FREE
S J C Shan, A Scorilas, D Katsaros and E P Diamandis
Br J Cancer 96: 362-372; doi:10.1038/sj.bjc.6603556
Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation FREE
T Harada, P Baril, R Gangeswaran, G Kelly, C Chelala, V Bhakta, K Caulee, P C Mahon and N R Lemoine
Br J Cancer 96: 373-382; doi:10.1038/sj.bjc.6603563
Frequent reduced expression of alpha-1B-adrenergic receptor caused by aberrant promoter methylation in gastric cancers FREE
H Noda, Y Miyaji, A Nakanishi, F Konishi and Y Miki
Br J Cancer 96: 383-390; doi:10.1038/sj.bjc.6603555
Estimating the referral rate for cancer genetic assessment from a systematic review of the evidence FREE
C Featherstone, A Colley, K Tucker, J Kirk and M B Barton
Br J Cancer 96: 391-398; doi:10.1038/sj.bjc.6603432
Letters to the Editor
Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? FREE
D B Costa and S Kobayashi
Br J Cancer 96: 399; advance online publication, January 16, 2007; doi:10.1038/sj.bjc.6603564
Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer FREE
H Asahina, K Yamazaki and I Kinoshita
Br J Cancer 96: 400; advance online publication, January 9, 2007; doi:10.1038/sj.bjc.6603565
Book Review
Gene expression profiling by microarrays – clinical implications FREE
J-P Gillet
Br J Cancer 96: 401; doi:10.1038/sj.bjc.6603486
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
